Isomerase and BugBiome team up for eco-friendly crop protection

Synthetic biology firm Isomerase has entered a strategic partnership with BugBiome to accelerate the discovery of novel bioinsecticides. The collaboration aims to leverage microbial compounds to develop targeted, sustainable agricultural solutions.

Under the agreement, BugBiome will gain non-exclusive research access to Isomerase’s extensive collection of approximately 7,000 proprietary actinomycete strains. These microorganisms have demonstrated diverse bioactivity, including pathogen resistance and enzyme inhibition. BugBiome will evaluate the strains using its insect behavioral screening platform, AvidX, to identify actives that deter crop pests while minimizing harm to beneficial organisms and the environment.

The partnership allows BugBiome to secure exclusive commercial rights to specific strains of interest. Financial details of the agreement were not disclosed.

BugBiome specializes in leveraging microbes for natural pest control solutions, utilizing its proprietary screening platform to decode insect-microbe interactions. The company is backed by Cambridge Angels, Discovery Park Ventures, and IndieBio/SOSV.

Isomerase, a leader in microbial and process discovery, supports partners in transforming early-stage concepts into scalable products. With expertise in strain engineering, protein discovery, and biocatalysis, the company operates from state-of-the-art laboratories in Chesterford Research Park and Solopark near Cambridge.

The collaboration reflects the shared commitment of both companies to reducing reliance on synthetic pesticides and developing innovative, eco-friendly solutions to agricultural challenges.